<DOC>
	<DOC>NCT02044848</DOC>
	<brief_summary>This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.</brief_summary>
	<brief_title>Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Males and females aged 1835 years initially (subjects aged 817 may be included at a later stage, starting with age 1217 years, followed by age 811 years). Body weight between 40120 kg initially (subjects weighing 2139 kg may be included at a later stage). Recent onset type 1 diabetes mellitus, diagnosed with 100 days of first dose. Peak stimulated Cpeptide levels &gt;/= 0.2 pmol/L following mixed meal tolerance test Any form of diabetes other than autoimmune type 1 (eg, type 2 diabetes, maturity onset diabetes of the young, latent autoimmune diabetes of the adult). Diabetic ketoacidosis within 2 weeks of screening. Pregnancy or lactation. Recent (within 2 weeks of screening), ongoing, chronic or recurrent infectious disease. Active infection with hepatitis B or C, EpsteinBarr virus, cytomegalovirus, or HIV. Tuberculosis infection. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>type 1 diabetes mellitus</keyword>
</DOC>